Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats.
Human metapneumovirus (hMPV) is a recently described paramyxovirus that is a major cause of upper and lower respiratory infection in children and adults worldwide. A safe and effective vaccine could decrease the burden of disease associated with this novel pathogen. We previously reported the development of the cotton rat model of hMPV infection and pathogenesis (J. V. Williams et al., J. Virol. 79:10944-10951, 2005). We report here the immunogenicity of an hMPV fusion (F) protein in this model. We constructed DNA plasmids that exhibited high levels of expression of hMPV F in mammalian cells (DNA-F). These constructs were used to develop a novel strategy to produce highly pure, soluble hMPV F protein lacking the transmembrane domain (FDeltaTM). We then immunized cotton rats at 0 and 14 days with either control vector, DNA-F alone, DNA-F followed by FDeltaTM protein, or FDeltaTM alone. All groups were challenged intranasally at 28 days with live hMPV. All three groups that received some form of hMPV F immunization mounted neutralizing antibody responses and exhibited partial protection against virus shedding in the lungs compared to controls. The FDeltaTM-immunized animals showed the greatest degree of protection (>1,500-fold reduction in lung virus titer). All three immunized groups showed a modest reduction of nasal virus shedding. Neither evidence of a Th2-type response nor increased lung pathology were present in the immunized animals. We conclude that sequence-optimized hMPV F protein protects against hMPV infection when delivered as either a DNA or a protein vaccine in cotton rats.
Cseke
Gabriella
G
Department of Chemistry, Vanderbilt University Medical Center, D-7235 Medical Center North, 1161 21st Ave. South, Nashville, TN 37232-2581, USA.
Wright
David W
DW
Tollefson
Sharon J
SJ
Johnson
Joyce E
JE
Crowe
James E
JE
Williams
John V
JV
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D004195:Disease Models, Animal; D006801:Humans; D007114:Immunization; D008168:Lung / Q000473:pathology / Q000821:virology; D029121:Metapneumovirus / Q000276:immunology*; D018184:Paramyxoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D016205:Sigmodontinae; D014760:Viral Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology
D000914:Antibodies, Viral; D014760:Viral Fusion Proteins; D014765:Viral Vaccines